CELL Key Statistics, Chart & Performance
The current stock price of CELL is 0.9981 USD. In the past month the price increased by 5.06%.
CELL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.87 | 217.71B | ||
| DHR | DANAHER CORP | 29.69 | 161.70B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 183 | 55.61B | ||
| A | AGILENT TECHNOLOGIES INC | 24.39 | 38.58B | ||
| IQV | IQVIA HOLDINGS INC | 19.38 | 38.39B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.32 | 28.48B | ||
| WAT | WATERS CORP | 29.91 | 22.61B | ||
| ILMN | ILLUMINA INC | 30.08 | 20.04B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.92 | 19.79B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.28 | 15.82B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B | ||
| TEM | TEMPUS AI INC | N/A | 10.51B |
Related stock screener links
About CELL
Company Profile
PhenomeX, Inc. is a biology company that engages in the study of cells. The company is headquartered in Emeryville, California and currently employs 285 full-time employees. The company went IPO on 2020-07-17. The firm enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The firm enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company’s platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.
Company Info
PHENOMEX INC
5858 Horton Street, Suite 320
Emeryville CALIFORNIA US
Employees: 285
Phone: 15108582855.0
PHENOMEX INC / CELL FAQ
What does PHENOMEX INC do?
PhenomeX, Inc. is a biology company that engages in the study of cells. The company is headquartered in Emeryville, California and currently employs 285 full-time employees. The company went IPO on 2020-07-17. The firm enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The firm enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company’s platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.
What is the current price of CELL stock?
The current stock price of CELL is 0.9981 USD. The price increased by 0.31% in the last trading session.
Does CELL stock pay dividends?
CELL does not pay a dividend.
How is the ChartMill rating for PHENOMEX INC?
CELL has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for CELL stock?
PHENOMEX INC (CELL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.38).
What is the expected growth for CELL stock?
The Revenue of PHENOMEX INC (CELL) is expected to decline by -10.41% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for PHENOMEX INC?
PHENOMEX INC (CELL) has a market capitalization of 98.79M USD. This makes CELL a Micro Cap stock.
CELL Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CELL.
CELL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CELL. CELL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CELL Financial Highlights
Over the last trailing twelve months CELL reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS decreased by -9.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.85% | ||
| ROE | -111.9% | ||
| Debt/Equity | 0 |
CELL Forecast & Estimates
11 analysts have analysed CELL and the average price target is 1.53 USD. This implies a price increase of 53.29% is expected in the next year compared to the current price of 0.9981.
For the next year, analysts expect an EPS growth of 17.97% and a revenue growth -10.41% for CELL